
Jazz Pharmaceuticals plc JAZZ
€ 162.10
-0.05%
Geschäftsbericht 2025
hinzugefügt 24.02.2026
Jazz Pharmaceuticals plc DPO 2011-2026 | JAZZ
DPO Jährlich Jazz Pharmaceuticals plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 136 | 122 | 80.8 | 77.6 | 77.6 | 78 | 75.1 | 74 | 134 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 136 | 74 | 95 |
DPO anderer Aktien in der Pharmaeinzelhändler
| Name | DPO | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals
ALNY
|
55 | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
72.6 | $ 0.44 | -16.64 % | $ 5.04 M | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
58.1 | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Cardiff Oncology
CRDF
|
406 | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
3.24 K | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
4.83 K | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Aquestive Therapeutics
AQST
|
395 | $ 4.09 | -0.97 % | $ 437 M | ||
|
Daré Bioscience
DARE
|
1.64 K | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
DBV Technologies S.A.
DBVT
|
28.6 K | $ 20.36 | -3.32 % | $ 2.84 B | ||
|
Dyadic International
DYAI
|
105 | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 31.37 | 1.0 % | $ 2.08 B |